Physician profile
Carla Trail
NPI 1184014524
$1,956.45
in general payments reported to CMS, 2019-2025
16 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $438 · 2022: $614 · 2023: $428 · 2024: $331 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644 · Education: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.98 |
| Education | $260.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $550.39 | 2021-2023 | |
| Janssen Biotech, INC. | $338.32 | 2021-2025 | Tremfya |
| Revance Therapeutics, INC. | $270.29 | 2024 | Daxxify |
| Sun Pharmaceutical Industries INC. | $193.76 | 2021-2024 | |
| Genzyme Corporation | $177.69 | 2022-2023 | |
| Dermavant Sciences, INC. | $89.25 | 2023 | Vtama |
| Janssen Scientific Affairs, LLC | $84.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Pfizer INC. | $40.62 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $38.05 | 2022-2023 | Dupixent |
| Boston Scientific Corporation | $28.17 | 2023-2025 | Solyx Sis System |
| Novartis Pharmaceuticals Corporation | $20.20 | 2022 | |
| Novo Nordisk INC | $19.00 | 2023 | |
| Lilly USA, LLC | $15.92 | 2025 | Ebglyss |
| Fresenius Kabi USA, LLC | $13.29 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Trail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.